PHI with peritoneal carcinomatosis
How does this condition affect your private health insurance?
Peritoneal carcinomatosis, or Peritonealkarzinom, refers to the widespread dissemination of cancer cells within the peritoneal cavity, the space lining the abdominal organs. It typically arises as a metastatic spread from primary cancers, most commonly gastrointestinal (e.g., colorectal, gastric, pancreatic) or ovarian cancer, but can also originate from primary peritoneal cancer. Symptoms often include abdominal pain, bloating, ascites (fluid accumulation), nausea, vomiting, and weight loss, indicating advanced disease. Diagnosis involves imaging, laparoscopy with biopsy, and tumor markers. Treatment is challenging and often palliative, focusing on symptom management, although cytoreductive surgery with HIPEC offers a curative intent for select patients.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months (from symptom onset to diagnosis/initial treatment)
Duration of Illness (Lifetime)
Chronic progressive, often leading to terminal illness within months to a few years
Cost of Treatment (Initial)
Very high (e.g., hundreds of thousands of dollars for surgery and initial chemotherapy)
Cost of Treatment (Lifetime)
Extremely high (e.g., several hundred thousand to over a million dollars, including ongoing palliative care)
Mortality Rate
High to very high (>80-90%), as it signifies advanced cancer
Risk of Secondary Damages
Very high (e.g., bowel obstruction, severe pain, malnutrition, ascites, significant psychological distress)
Probability of Full Recovery
Low (<10%), primarily for highly selected patients undergoing aggressive multi-modal therapy
Underlying Disease Risk
Very high (nearly 100%, as it is almost always a metastatic spread from a primary cancer like ovarian, colorectal, or gastric cancer)